This study aimed to assess the plasma levels of TGF-β1, active-TGF-β1, VEGF-A, and FGF2 in patients with FD and their correlation with the other progression of FD-associated cardiomyopathy. The gene discussed is FGF2; the disease is cardiomyopathy.